Second-line tarlatamab improves OS in SCLC Summary Second-line treatment with tarlatamab, a DLL3-targeting bispecific T-cell engager, significantly improved overall survival (OS) in patients with relapsed or refractory small cell lung cancer (SCLC) compared to Read More
Tags :Randomized controlled trials
Education, Research & Positions
Adding durvalumab to perioperative FLOT improves gastric cancer outcomes
Adding durvalumab to perioperative FLOT improves gastric cancer outcomes Summary Adding the immunotherapy drug durvalumab to the standard perioperative chemotherapy regimen FLOT significantly improves outcomes for patients with resectable gastric or gastroesophageal junction cancer. The Read More
Site Logo
Powered by AI
New Journal Citation Reports (JCR) 2025
All-Time Views
930K+ and Counting..!
Follow me on Linkedin for Latest Jobs and Scholarships
Join WhatsApp
Click the ICON to Join
Subscribe Youtube
Celebrating 6 Years
Now, it has been 6 years since it was launched in late July 2018 and is moving forward. Appreciate all the respected visitors! Please share this site with your friends to push science forward and improve human health.
Site Trust Score
Google Safe
